Exploration of Structure-Activity Relationship Using Integrated Structure and Ligand Based Approach: Hydroxamic Acid-Based HDAC Inhibitors and Cytotoxic Agents.

IF 1.8 Q3 PHARMACOLOGY & PHARMACY Turkish Journal of Pharmaceutical Sciences Pub Date : 2023-08-22 DOI:10.4274/tjps.galenos.2022.12269
Ekta Shirbhate, Jaiprakash Pandey, Vijay Kumar Patel, Ravichandran Veerasamy, Harish Rajak
{"title":"Exploration of Structure-Activity Relationship Using Integrated Structure and Ligand Based Approach: Hydroxamic Acid-Based HDAC Inhibitors and Cytotoxic Agents.","authors":"Ekta Shirbhate,&nbsp;Jaiprakash Pandey,&nbsp;Vijay Kumar Patel,&nbsp;Ravichandran Veerasamy,&nbsp;Harish Rajak","doi":"10.4274/tjps.galenos.2022.12269","DOIUrl":null,"url":null,"abstract":"<p><p>The present study aimed to establish significant and validated quantitative structure-activity relationship (QSAR) models for histone deacetylase (HDAC) inhibitors and correlate their physicochemical, steric, and electrostatic properties with their anticancer activity. We have selected a dataset from earlier research findings. The target and ligand molecules were procured from recognized databases and incorporated into pivotal findings such as molecular docking (XP glide), e-pharmacophore study and 3D QSAR model designing study (phase). Docking revealed molecule 39 with better docking score and well binding contact with the protein. 3D QSAR analysis, which was performed for partial least squares factor 5 reported good 0.9877 and 0.7142 as R2 and Q2 values and low standard of deviation: 0.1049 for hypothesis AADRR.139. Based on the computational outcome, it has been concluded that molecule 39 is an effective and relevant candidate for inhibition of HDAC activity. Moreover, these computational approaches motivate to discover novel drug candidates in pharmacological and healthcare sectors.</p>","PeriodicalId":23378,"journal":{"name":"Turkish Journal of Pharmaceutical Sciences","volume":"20 4","pages":"270-284"},"PeriodicalIF":1.8000,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445225/pdf/TJPS-20-270.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/tjps.galenos.2022.12269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

The present study aimed to establish significant and validated quantitative structure-activity relationship (QSAR) models for histone deacetylase (HDAC) inhibitors and correlate their physicochemical, steric, and electrostatic properties with their anticancer activity. We have selected a dataset from earlier research findings. The target and ligand molecules were procured from recognized databases and incorporated into pivotal findings such as molecular docking (XP glide), e-pharmacophore study and 3D QSAR model designing study (phase). Docking revealed molecule 39 with better docking score and well binding contact with the protein. 3D QSAR analysis, which was performed for partial least squares factor 5 reported good 0.9877 and 0.7142 as R2 and Q2 values and low standard of deviation: 0.1049 for hypothesis AADRR.139. Based on the computational outcome, it has been concluded that molecule 39 is an effective and relevant candidate for inhibition of HDAC activity. Moreover, these computational approaches motivate to discover novel drug candidates in pharmacological and healthcare sectors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于集成结构和配体方法的构效关系探索:基于羟肟酸的HDAC抑制剂和细胞毒性药物。
本研究旨在建立有意义且有效的组蛋白去乙酰化酶(HDAC)抑制剂的定量构效关系(QSAR)模型,并将其理化、位阻和静电特性与抗癌活性联系起来。我们从早期的研究成果中选择了一个数据集。靶标和配体分子从公认的数据库中获取,并纳入关键发现,如分子对接(XP滑翔),电子药效团研究和3D QSAR模型设计研究(阶段)。对接发现分子39对接得分较高,与蛋白结合良好。对偏最小二乘因子5进行三维QSAR分析,R2和Q2值分别为0.9877和0.7142,假设AADRR.139的标准偏差较低,为0.1049。基于计算结果,我们得出结论,分子39是抑制HDAC活性的有效候选物。此外,这些计算方法激励在药理学和医疗保健部门发现新的候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.60
自引率
5.90%
发文量
79
期刊最新文献
A Novel Controlled Release Implant of Insulin Based on Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymer Prepared by Extrusion. Optimization of Enterocin Production from Probiotic Enterococcus faecium Using Taguchi Experimental Design. Evaluation of a Synthetic PEI-based Polymeric Vector for ING4 Gene Delivery to MCF-7 Breast Cancer Cells Evaluation of Anticancer and Antioxidant Activities of Coffee Stem Parasite Extract (Scurrula Ferruginea (Roxb. Ex Jack) Danser) and in Silico Studies of its Isolate Development of Cyclosporine A Nanosuspension using Experimental Design by Response Surface Methodology: In Vitro Evaluations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1